IP Verse

Accord Healthcare vs. Sanofi Mature - UPC_CFI_463/2024

The case UPC_CFI_463/2024 was filed by the plaintiff Accord Healthcare against the defendant Sanofi Mature on 30 Aug, 2024.

Case Timeline

30 Aug, 2024
Case Filed
30 Aug, 2024
Counterclaim for Revocation
10 Sep, 2025
Written Procedure
10 Sep, 2025
Rejoinder
10 Sep, 2025
Interim Conference
10 Sep, 2025
Oral Procedure
Today Nov 1, 2025
Decision

Case Details

    Case Number:

    UPC_CFI_463/2024

    Patent Number:

    EP2493466

    Filing Date:

    30 Aug, 2024

    Proceeding Type:

    Counter Claim For Revocation

    Case Phase:

    Interim Phase

    Plaintiffs:

    • Accord Healthcare
    • Accord Healthcare AB
    • Accord Healthcare Italia
    • Accord Healthcare SLU

    Plaintiff Representative:

    • Jules Fabre

    Defendants:

    • Sanofi Mature

    Defendant Representative:

    • Frédéric CHEVALLIER

    Judges:

    • Alima Zana
    • Matthias Zigann
    • Tobias Pichlmaier

    Court Division:

    First Instance, Local Division - Munich

Case Decision

Decision pending - set alert to receive updates

Docket Entries

The docket entries provide a comprehensive overview of all filings, motions, orders, and other significant actions taken in the case.

Last updated on: Oct 30, 2025
DateTitle

Notify me when new UPC document is filed

Oct 11, 2025Final Order
Oct 11, 2025Action.Phasechange
Oct 11, 2025Action.Issuedecision
Oct 10, 2025Signature Image
Oct 10, 2025Receipt
Oct 10, 2025Other Document
Oct 10, 2025Cover Sheet
Oct 10, 2025Application
Oct 8, 2025Receipt
Oct 8, 2025Further Pleadings
Oct 8, 2025Exhibit
Oct 8, 2025Cover Sheet
Sep 15, 2025Oral Hearing Reference Ic
Sep 10, 2025Written Procedure Closure
Sep 10, 2025Interim Conference Decision
Sep 10, 2025Fix Interim Conference Date
Aug 8, 2025Rejoinder
Aug 8, 2025Exhibit No. B.22
Aug 8, 2025Exhibit No. B.2.2
Aug 8, 2025Exhibit No. B.2.2
Aug 8, 2025Exhibit No. B
Aug 8, 2025Exhibit No. B
Aug 8, 2025Exhibit No. B
Aug 8, 2025Exhibit No. B
Aug 8, 2025Exhibit No. B
Aug 8, 2025Exhibit No. B
Aug 8, 2025Exhibit No. B
Aug 8, 2025Exhibit No. B
Aug 8, 2025Exhibit No. B
Aug 8, 2025Exhibit No. B
Aug 8, 2025Exhibit No. B
Aug 8, 2025Exhibit No. B
Aug 8, 2025Exhibit No. B
Aug 8, 2025Exhibit No. B
Aug 8, 2025Exhibit No. 0
Aug 8, 2025Acknowledgement Of Lodging
Jul 16, 2025Outcome Of The Order
Jul 16, 2025262 A Final (Again For The Old)
Jul 16, 2025262 A Final
Jul 11, 2025Acknowledgement Of Change Of A Representative
Jul 9, 2025Exhibit Tw 8.9 Upc Cfi 145 (Ld Munich) Order Of 8 May Redacted Version
Jul 9, 2025Exhibit Tw 8.8 Upc Cfi 145 (Ld Munich) Order Of 27 February
Jul 9, 2025Exhibit Tw 8.7 Upc Cfi 145 (Ld Munich) Order Of 22 January
Jul 9, 2025Exhibit Tw 8.6 Upc Cfi 145 (Ld Munich) Order Of 14 January
Jul 9, 2025Exhibit Tw 8.5 Upc Cfi 145 (Ld Munich) Order Of 9 January
Jul 9, 2025Exhibit Tw 8.4 Upc Cfi 145 (Ld Munich) Order Of 3 January
Jul 9, 2025Exhibit Tw 8.3 Upc Cfi 145 (Ld Munich) Order Of 19 December
Jul 9, 2025Exhibit Tw 8.2 Upc Cfi 145 (Ld Munich) Order Of 5 November
Jul 9, 2025Exhibit Tw 8.1 Upc Cfi 145 (Ld Munich) Orders Of 1St October
Jul 9, 2025Exhibit Tw 8.16 Accord S Comments On Sanofi S Further Amended Requests Filed 9 April
Jul 9, 2025Exhibit Tw 8.15 Official Communication 3 March From Accord Upc Representatives To Sanofi Upc Representatives
Jul 9, 2025Exhibit Tw 8.14 Accord Comments On Sanofi Amended Requests And Rejoinder To Sanofi Comments Filed On 12 February .
Jul 9, 2025Exhibit Tw 8.13 Accord Comments On 262A Sanofi S Request Filed On 12 November
Jul 9, 2025Exhibit Tw 8.12 Accord S Rejoinder To The Sanofi S Comments On The Preliminary Objections Filed 11 October
Jul 9, 2025Exhibit Tw 8.11 Accord S Preliminary Objections And Generic Procedural Application Filed 1 July
Jul 9, 2025Exhibit Tw 8.10 Upc Cfi 148 (Ld Munich) Order Of 27 June
Jul 9, 2025Exhibit Tw 7.2 Extracts W Tilmann And C Plasmann Unified Patent Protection In Europe A Commentary Book 1St Ed Published
Jul 9, 2025Exhibit Tw 6.5 Schedule Of Costs For The Defendants As Of 8 July (Signed)
Jul 9, 2025Exhibit Tw 6.4 Sanofi Winthrop Industries Annuals Report For The Period
Jul 9, 2025Exhibit Tw 6.3 Paris Court Judgment Issued On 6 September Accord V Sanofi Rg 21 06416
Jul 9, 2025Exhibit Tw 5.35Bis Sanofi Annual Report 20 F In The Us (Complete Version)
Jul 9, 2025Act 16112 And Accord Reply To The Defence To The Counterclaim And Rejoinder Unredacted Version 8 July 202
Jul 9, 2025Act 16112 And Accord Reply To The Defence To The Counterclaim And Rejoinder Redacted Version 8 July .
Jul 9, 2025Act 16112 And Accord Application 262A Rop 8 July
Jul 9, 2025Acknowledgement Of Lodging
Jul 8, 2025Formal Checks Notification Of Positive Outcome
Jul 8, 2025Application Rop293 Receipt
Jun 27, 2025Application Rop293
Jun 27, 2025Application
May 23, 2025Acknowledgement Of Change Of A Representative
May 22, 2025Formal Checks Notification Of Positive Outcome
May 22, 2025Application Rop293 Receipt
May 22, 2025Application Rop293
May 22, 2025Application Change Of Representative Jules Fabre Signed
May 22, 2025Acknowledgement Of Change Of A Representative
May 21, 2025Formal Checks Notification Of Positive Outcome
May 21, 2025Application Rop293 Receipt
May 19, 2025Application Rop293
May 19, 2025Application Change Of Representative
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order
Jan 16, 2025Hearing Reference
Jan 13, 2025R 305 Second Oral Comments
Jan 13, 2025Hearing Dates
Jan 9, 2025Receipt
Jan 9, 2025Exhibit No. A.02
Jan 9, 2025Application
Dec 19, 2024Outcome Of The Order
Dec 19, 2024Extension Request
Dec 10, 2024Receipt
Dec 9, 202412 09 Accord Request For Extension Of Deadline
Dec 5, 2024Acknowledgement Of Lodging
Dec 5, 202412 05 Application To Change Details Of A Representative 64597
Nov 1, 2024Reply And Defence
Nov 1, 2024Formal Checks Notification Of Positive Outcome
Nov 1, 2024Acknowledgement Of Lodging
Sep 17, 2024Epouploaddocumentsworkflow
Sep 16, 2024Document From Epo
Sep 6, 2024Panel Appointment
Sep 6, 2024Notification Of Service
Sep 6, 2024Epo Request For Case Pending
Sep 6, 2024Acknowledgement Of Lodging
Sep 6, 2024Acknowledgement Of Access To Case
Sep 4, 2024Formal Checks Notification Of Positive Outcome
Aug 30, 2024Exhibit Pm 7.1 Extract Paul England A Practioners Guide To The Upc And Up Dec
Aug 30, 2024Exhibit Pm 6.2 Order 7 June First Instance Court
Aug 30, 2024Exhibit Pm 6.1 Excerpts Iqvia Audit Data Presentation July
Aug 30, 2024Exhibit Pm 5.9 Ich Topic E8 Note For Guidance On General Considerations For Clinical Trials March 1998
Aug 30, 2024Exhibit Pm 5.8 Tannock Et Al. Chemotherapy With Mitoxantrone Plus Prednisone (...)1996 Jun.
Aug 30, 2024Exhibit Pm 5.7 Tannock Et Al. Docetaxel Plus Prednisone Or Mitoxantrone Plus Prednisone (...) Oct.
Aug 30, 2024Exhibit Pm 5.6 Extracts From The Summary Of Product Characteristics Of Taxotere
Aug 30, 2024Exhibit Pm 5.5 Us 065138 A1
Aug 30, 2024Exhibit Pm 5.4 Declaration By Prof. Stefan Muller
Aug 30, 2024Exhibit Pm 5.3 Declaration By Dr. Kurt Miller
Aug 30, 2024Exhibit Pm 5.36 Galletti Et Al. Paclitaxel And Docetaxel Resistance (...)
Aug 30, 2024Exhibit Pm 5.35 Extracts Sanofi Annual Report 20 F In The Us
Aug 30, 2024Exhibit Pm 5.34 Fitzpatrick Et Al. Treatment Decisions For Advanced Genitourinary (...)
Aug 30, 2024Exhibit Pm 5.33 Extracts From Sanofi Annual Report
Aug 30, 2024Exhibit Pm 5.32 Madan Et Al. Overcoming Chemotherapy Resistance In Prostate Cancer (...) June
Aug 30, 2024Exhibit Pm 5.31 Kumar Pal Et Al. CR Itical Appraisal Of Cabazitaxel (...) Clinical Interventions In Aging
Aug 30, 2024Exhibit Pm 5.30 Screenshot From Openpaymentsdata.
Aug 30, 2024Exhibit Pm 5.2 Annexes To The Declaration By Dr Samuel Denmaede (Part 4)
Aug 30, 2024Exhibit Pm 5.2 Annexes To The Declaration By Dr Samuel Denmaede (Part 3)
Aug 30, 2024Exhibit Pm 5.2 Annexes To The Declaration By Dr. Samuel Denmaede (Part 2)
Aug 30, 2024Exhibit Pm 5.2 Annexes To The Declaration By Dr. Samuel Denmaede (Part 1)
Aug 30, 2024Exhibit Pm 5.29 Extracts From Dr. Sartor Deposition Transcript Of 8 May In The Us Proceedings
Aug 30, 2024Exhibit Pm 5.28 Declaration By Dr. Sartor Before The Patent And Trial And Appeal Board 20 April
Aug 30, 2024Exhibit Pm 5.27 Declaration By Dr. Sartor Of 23 December
Aug 30, 2024Exhibit Pm 5.26 Correspondence In The Lancet () Re Pm 5.25 Froehner And Wirth V. De Bono
Aug 30, 2024Exhibit Pm 5.25 De Bono Et Al. Prednisone Plus Cabazitaxel Or Mitoxantrone (...) The Lancet
Aug 30, 2024Exhibit Pm 5.24 Screenshot From Clinicaltrial.Gov Xrp6258 Plus Prednisone Compared To (...) 3 May
Aug 30, 2024Exhibit Pm 5.23 Wayback Machine Extracts From Clinicaltrial.Gov. And
Aug 30, 2024Exhibit Pm 5.22 Sanofi Press Release DATED 21 December
Aug 30, 2024Exhibit Pm 5.21 Tropic Trial Protocol In A Document Entitled Cabazitaxel (Xrp 6258) For Hormone (...)
Aug 30, 2024Exhibit Pm 5.20 Beardsley Et Al. Systemic Therapy After First Line Docetaxel (...)
Aug 30, 2024Exhibit Pm 5.1 Declaration By Dr. Samuel Denmeade
Aug 30, 2024Exhibit Pm 5.19 Pivot Et Al. A Multicenter Phase Ii Study Of Xrp6258 (...)
Aug 30, 2024Exhibit Pm 5.18 Mita Et Al. Phase I And Pharmacokinetic Study Of Xrp6258 (...)
Aug 30, 2024Exhibit Pm 5.17 Berthold Et Al. Survival And Psa Response Of Patients In The Tax 327 Study
Aug 30, 2024Exhibit Pm 5.16 Oudard Et Al. Multicenter Randomized Phase Ii Study (...) May
Aug 30, 2024Exhibit Pm 5.15 Petrylak Et Al. Docetaxel And Estramustine Compared (...) Oct.
Aug 30, 2024Exhibit Pm 5.14 Label Novantrone (Mitoxantrone) Fda
Aug 30, 2024Exhibit Pm 5.13 Scher Et Al. Design And End Points Of Clinical Trials For Patients (...)
Aug 30, 2024Exhibit Pm 5.12 Declaration Of Helsinki Ethical Principles Of Medical Research Involving Human Subjects October
Aug 30, 2024Exhibit Pm 5.11 Wong And Siah Estimation Of Clinical Trial Success Rates And Related Parameters Biostatistics
Aug 30, 2024Exhibit Pm 5.10 Chmp Guideline On The Evaluation Of Anticancer Medicinal Products In Man December
Aug 30, 2024Exhibit Pm 4.9 Further Observations Accord Of 10 December
Aug 30, 2024Exhibit Pm 4.8 Notice Of Opposition Accord Of 10 March
Aug 30, 2024Exhibit Pm 4.7 Record Of The Assignment Of EP466During Its Examination Before The Epo
Aug 30, 2024Exhibit Pm 4.6 Summons To Oral Proceedings By The Board Of Appeal And Date Confirmation
Aug 30, 2024Exhibit Pm 4.5 Extracts From The European Patent Register For EP2493466As At 21 August
Aug 30, 2024Exhibit Pm 4.4 Priority Document No. US61293903(P2)
Aug 30, 2024Exhibit Pm 4.3 Priority Document No. US61256160(P1)
Aug 30, 2024Exhibit Pm 4.2 Wo 051894 A1
Aug 30, 2024Exhibit Pm 4.1 Ep E 493 466 B1
Aug 30, 2024Exhibit Pm 4.14 Ip.Appify Blog Of 12 January Caselaw Epo Reviews Of Epo Boa Decisions Of D.X. Thomas
Aug 30, 2024Exhibit Pm 4.13 Decision Of The United States Patent Office (Uspto) Of 22 October
Aug 30, 2024Exhibit Pm 4.12 Grounds Of Appeal Accord Of 24 May
Aug 30, 2024Exhibit Pm 4.11 Notice Of Appeal Accord Of 15 January
Aug 30, 2024Exhibit Pm 4.10 Opposition Division Reasoned Decision Dated On 25 January
Aug 30, 2024Exhibit Pm 3.1 Summary Of Product Characteristics Of Cabazitaxel Accord
Aug 30, 2024Exhibit Pm 2.8 Sales Of Jevtana In European Countries In (Based On Iqvia Data)
Aug 30, 2024Exhibit Pm 2.7 Revue Prescrire Cabazitaxel Jevtana Trop Toxique Pour Une Efficacite Trop Incertaine October
Aug 30, 2024Exhibit Pm 2.6 Opinion Of The Transparency Committee Of The French National Health Authority 17 October
Aug 30, 2024Exhibit Pm 2.5 Refusal Notice Issued By The Inesss In February
Aug 30, 2024Exhibit Pm 2.4 Le Monde Sanofi Londres Refuse De Rembourser Le Jevtana Of 13 January
Aug 30, 2024Exhibit Pm 2.3 Opinion Of The Transparency Committee Of The French National Health Authority Of 19 October
Aug 30, 2024Exhibit Pm 2.2 Neutropenia Msd Manual
Aug 30, 2024Exhibit Pm 2.1 Summary Of Product Characteristics Of Jevtana
Aug 30, 2024Exhibit Pm 1.3 Communication From The Paris Court Of First Instance DATED 5 July
Aug 30, 2024Exhibit Pm 1.2 Extract Sanofi Annual Reports
Aug 30, 2024Exhibit Pm 1.1 French Company Registry Extract For Sanofi Mature Ip
Aug 30, 2024Act 16112 And 4499 2024 Accord Statement Of Defence And Counterclaim For Revocation 30 August
Aug 30, 202444999 Proof Of Court Fees Payment

More cases involving EP2493466B1

This table lists the related cases associated with the patent, including case numbers, plaintiffs, and defendants involved in each case.

Last updated on: Oct 30, 2025
Case NumberFiling DatePlaintiffsDefendants
CC_48036/2024Sep 2, 2024Stada Arzneimittel, Stada Nordic, StadapharmSanofi, Sanofi Aventis, Sanofi Aventis Deutschland, Sanofi Aventis France, Sanofi Belgium, Sanofi Mature, Sanofi Produtos Farmaceuticos LDA, Sanofi Winthrop Industrie
CC_49716/2024Sep 2, 2024Zentiva, Zentiva France, Zentiva PharmaSanofi Mature
UPC_CFI_496/2024Sep 2, 2024Stada Arzneimittel, Stada Nordic, StadapharmSanofi, Sanofi AB, Sanofi Aventis, Sanofi Aventis Deutschland, Sanofi Aventis France, Sanofi Belgium, Sanofi Mature, Sanofi Produtos Farmaceuticos LDA, Sanofi Winthrop Industrie

More cases involving Accord Healthcare

This table lists the related cases associated with the patent, including case numbers, plaintiffs, and defendants involved in each case.

Last updated on: Oct 30, 2025
Case NumberFiling DatePlaintiffsDefendants
APP_32587/2025Jul 8, 2025Accord Healthcare, Accord Healthcare AB, Accord Healthcare Italia, Accord Healthcare SLUSanofi, Sanofi AB, Sanofi Aventis, Sanofi Aventis Deutschland, Sanofi Belgium, Sanofi Mature, Sanofi Produtos Farmaceuticos LDA, Sanofi Winthrop Industrie
APP_32588/2025Jul 8, 2025Accord Healthcare, Accord Healthcare AB, Accord Healthcare Italia, Accord Healthcare SLUSanofi Mature
ACT_61148/2024Nov 14, 2024Accord Healthcare, Accord Healthcare SLUNovartis

More cases involving Sanofi Mature

This table lists the related cases associated with the patent, including case numbers, plaintiffs, and defendants involved in each case.

Last updated on: Oct 30, 2025
Case NumberFiling DatePlaintiffsDefendants
ORD_33148/2025Jul 17, 2025Sanofi MatureStada Arzneimittel, Stada Nordic, Stadapharm
APP_32509/2025Jul 8, 2025Betapharm Arzneimittel, DR Reddys, Reddy PharmaSanofi Mature
APP_32523/2025Jul 8, 2025Betapharm Arzneimittel, DR Reddys, Reddy PharmaSanofi Mature